InvestSMART

Avecho Biotechnology Limited (ASX:AVE)

ALERT: Price-sensitive ASX Announcement for AVE
Current share price for AVE : $0.023 0.011 (91.67%)+
Announcement
Release
22 May 2026 9:41AM
Price at Release
$0.012
Full Release
download
Summary
Avecho Biotechnology Limited announced the receipt of $1.98 million under the Australian Government's Research and Development Tax Incentive Scheme for the year ending December 31, 2025. This funding supports Avecho's ongoing commitment to developing cannabinoid formulations for pharmaceutical registration. The funds will be used to repay advances to Endpoint Capital, support operations, and further Avecho's commercialization strategy. Avecho is involved in developing innovative health products using its proprietary TPM® drug delivery system, with a focus on a Phase III clinical trial for CBD soft-gel capsules aimed at treating insomnia.
Key Points
  • Avecho received $1.98 million from the Australian Government's R&D Tax Incentive Scheme.
  • The funds will repay $1.62 million to Endpoint Capital.
  • Funds will also support company operations and commercialization strategies.
  • Avecho focuses on cannabinoid formulations for pharmaceutical registration.
  • Avecho is conducting a Phase III trial for CBD TPM soft-gel capsules for insomnia treatment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.